ASX - By Stock
|
IMU |
Re:
Breaking 12 cents
|
|
Mat.B
|
80 |
41K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
80
|
41K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Breaking 12 cents
|
|
Mat.B
|
80 |
41K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
80
|
41K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Breaking 12 cents
|
|
Mat.B
|
80 |
41K |
5 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
80
|
41K
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Breaking 12 cents
|
|
Mat.B
|
80 |
41K |
4 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
80
|
41K
|
4
|
|
ASX - By Stock
|
IMU |
Re:
Breaking 12 cents
|
|
Mat.B
|
80 |
41K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
80
|
41K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Breaking 12 cents
|
|
Mat.B
|
80 |
41K |
3 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
80
|
41K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Breaking 12 cents
|
|
Mat.B
|
80 |
41K |
10 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
80
|
41K
|
10
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 onCARlytics Trial Doses First Intravenous Patient
|
|
Mat.B
|
104 |
62K |
2 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
104
|
62K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Aus Super IMUOE Class Action
|
|
Mat.B
|
93 |
46K |
6 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
93
|
46K
|
6
|
|
ASX - By Stock
|
IMU |
Re:
IMU product line - PD1-Vaxx
|
|
Mat.B
|
44 |
21K |
9 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
44
|
21K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
IMU product line - HER-Vaxx
|
|
Mat.B
|
57 |
24K |
6 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
57
|
24K
|
6
|
|
ASX - By Stock
|
IMU |
Re:
IMU product line - PD1-Vaxx
|
|
Mat.B
|
44 |
21K |
12 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
44
|
21K
|
12
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
Mat.B
|
324 |
107K |
37 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
324
|
107K
|
37
|
|
ASX - By Stock
|
IMU |
Re:
AGM 2023 discussion
|
|
Mat.B
|
11 |
4.0K |
11 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
11
|
4.0K
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Investor Webinar featuring COO, Dr Glover & CMO, Dr Woodard
|
|
Mat.B
|
274 |
112K |
4 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
274
|
112K
|
4
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial
|
|
Mat.B
|
242 |
115K |
4 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
242
|
115K
|
4
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Investor Webinar - MAST Study Update
|
|
Mat.B
|
228 |
98K |
32 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
228
|
98K
|
32
|
|
ASX - By Stock
|
IMU |
Re:
SPP uptake
|
|
Mat.B
|
153 |
58K |
2 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
153
|
58K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
SPP uptake
|
|
Mat.B
|
153 |
58K |
0 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
153
|
58K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
SPP uptake
|
|
Mat.B
|
153 |
58K |
27 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
153
|
58K
|
27
|
|
ASX - By Stock
|
IMU |
Re:
SPP uptake
|
|
Mat.B
|
153 |
58K |
43 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
153
|
58K
|
43
|
|
ASX - By Stock
|
IMU |
Re:
Prediction
|
|
Mat.B
|
31 |
17K |
3 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
31
|
17K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Mat.B
|
27K |
13M |
8 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
27K
|
13M
|
8
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Mat.B
|
27K |
13M |
4 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
27K
|
13M
|
4
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Mat.B
|
27K |
13M |
12 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
27K
|
13M
|
12
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Mat.B
|
27K |
13M |
50 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
27K
|
13M
|
50
|
|
ASX - By Stock
|
IMU |
Re:
General Comments IMU
|
|
Mat.B
|
431 |
218K |
1 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
431
|
218K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene HER-Vaxx and CF33 Platforms To Feature at ASCO
|
|
Mat.B
|
56 |
27K |
6 |
16/12/22 |
16/12/22 |
ASX - By Stock
|
56
|
27K
|
6
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene to Present at J.P. Morgan Healthcare Conference
|
|
Mat.B
|
187 |
89K |
0 |
13/12/22 |
13/12/22 |
ASX - By Stock
|
187
|
89K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Mat.B
|
15K |
7.6M |
23 |
04/11/22 |
04/11/22 |
ASX - By Stock
|
15K
|
7.6M
|
23
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Mat.B
|
15K |
7.6M |
11 |
02/11/22 |
02/11/22 |
ASX - By Stock
|
15K
|
7.6M
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Mat.B
|
15K |
7.6M |
11 |
02/11/22 |
02/11/22 |
ASX - By Stock
|
15K
|
7.6M
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Mat.B
|
15K |
7.6M |
2 |
02/11/22 |
02/11/22 |
ASX - By Stock
|
15K
|
7.6M
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Mat.B
|
15K |
7.6M |
30 |
01/11/22 |
01/11/22 |
ASX - By Stock
|
15K
|
7.6M
|
30
|
|
ASX - By Stock
|
IMU |
Re:
Ann: First patient dosed in VAXINIA intratumoral cohort 2
|
|
Mat.B
|
18 |
15K |
3 |
31/10/22 |
31/10/22 |
ASX - By Stock
|
18
|
15K
|
3
|
|
ASX - By Stock
|
PLS |
Re:
Are you PLS' longest shareholder ?
|
|
Mat.B
|
152 |
87K |
9 |
06/10/22 |
06/10/22 |
ASX - By Stock
|
152
|
87K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Ann: OGTR grants VAXINIA DIR licence allowing trial expansion
|
|
Mat.B
|
137 |
76K |
29 |
20/09/22 |
20/09/22 |
ASX - By Stock
|
137
|
76K
|
29
|
|
ASX - By Stock
|
IMU |
Re:
Ann: IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT
|
|
Mat.B
|
327 |
155K |
2 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
327
|
155K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Trading Halt
|
|
Mat.B
|
255 |
160K |
5 |
12/09/22 |
12/09/22 |
ASX - By Stock
|
255
|
160K
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Trading Halt
|
|
Mat.B
|
255 |
160K |
9 |
12/09/22 |
12/09/22 |
ASX - By Stock
|
255
|
160K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
|
|
Mat.B
|
104 |
65K |
7 |
02/09/22 |
02/09/22 |
ASX - By Stock
|
104
|
65K
|
7
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
|
|
Mat.B
|
104 |
65K |
1 |
02/09/22 |
02/09/22 |
ASX - By Stock
|
104
|
65K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
|
|
Mat.B
|
104 |
65K |
9 |
01/09/22 |
01/09/22 |
ASX - By Stock
|
104
|
65K
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
|
|
Mat.B
|
104 |
65K |
58 |
01/09/22 |
01/09/22 |
ASX - By Stock
|
104
|
65K
|
58
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
|
|
Mat.B
|
104 |
65K |
6 |
01/09/22 |
01/09/22 |
ASX - By Stock
|
104
|
65K
|
6
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
|
|
Mat.B
|
104 |
65K |
5 |
01/09/22 |
01/09/22 |
ASX - By Stock
|
104
|
65K
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Mat.B
|
15K |
7.6M |
52 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
15K
|
7.6M
|
52
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
|
|
Mat.B
|
73 |
56K |
24 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
73
|
56K
|
24
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene appoints experienced life sciences CFO Mike Tonroe
|
|
Mat.B
|
75 |
41K |
27 |
18/07/22 |
18/07/22 |
ASX - By Stock
|
75
|
41K
|
27
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Final HER-Vaxx Phase 2 Trial Overall Survival Results
|
|
Mat.B
|
439 |
232K |
10 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
439
|
232K
|
10
|
|